Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study
Go back to Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study| Edwards Lifesciences (NYSE: EW) | Delayed: 92.01 -2.43 (2.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $94.44 | 52 Week High | $166.87 | |||
| Open | $94.55 | 52 Week Low | $72.20 | |||
| Day High | $95.34 | P/E | 26.75 | |||
| Day Low | $91.87 | EPS | $3.44 | |||
| Volume | 6,044,686 | |||||



